Van ECK Associates Corp Sells 9,751 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Van ECK Associates Corp cut its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 8.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 111,088 shares of the medical research company's stock after selling 9,751 shares during the period. Van ECK Associates Corp owned approximately 0.06% of IQVIA worth $21,829,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Private Trust Co. NA lifted its stake in IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock worth $115,000 after purchasing an additional 47 shares during the last quarter. Clear Harbor Asset Management LLC lifted its stake in IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company's stock worth $941,000 after purchasing an additional 50 shares during the last quarter. Pine Valley Investments Ltd Liability Co lifted its stake in IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after purchasing an additional 50 shares during the last quarter. Fortitude Family Office LLC lifted its stake in IQVIA by 2.9% in the third quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company's stock worth $468,000 after purchasing an additional 56 shares during the last quarter. Finally, Huntington National Bank lifted its stake in IQVIA by 7.4% in the third quarter. Huntington National Bank now owns 809 shares of the medical research company's stock worth $192,000 after purchasing an additional 56 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on IQV. TD Cowen lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Stephens began coverage on shares of IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 price objective for the company. Leerink Partners reaffirmed an "outperform" rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. UBS Group lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $251.22.

Insider Activity at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is owned by insiders.

IQVIA Stock Up 0.1 %

Shares of NYSE:IQV traded up $0.13 during trading on Tuesday, reaching $193.57. 480,108 shares of the stock traded hands, compared to its average volume of 1,368,497. The stock has a 50-day moving average of $200.15 and a two-hundred day moving average of $217.43. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The stock has a market cap of $35.13 billion, a P/E ratio of 25.82, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.